AquaBounty Technologies, Inc. (NASDAQ:AQB) Sees Large Decrease in Short Interest

AquaBounty Technologies, Inc. (NASDAQ:AQB) saw a large drop in short interest in January. As of January 30th, there was short interest totaling 17,318 shares, a drop of 25.9% from the January 15th total of 23,366 shares. Based on an average daily trading volume, of 39,938 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.5% of the company’s shares are sold short. Approximately 0.5% of the company’s shares are sold short. Based on an average daily trading volume, of 39,938 shares, the days-to-cover ratio is currently 0.4 days.

AquaBounty Technologies Trading Up 1.1%

Shares of AquaBounty Technologies stock opened at $0.90 on Friday. The stock’s fifty day moving average price is $0.93 and its 200-day moving average price is $1.13. The firm has a market cap of $3.49 million, a P/E ratio of -1.08 and a beta of 1.28. AquaBounty Technologies has a 12 month low of $0.50 and a 12 month high of $2.95.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AquaBounty Technologies in a research report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Investors Weigh In On AquaBounty Technologies

A hedge fund recently bought a new stake in AquaBounty Technologies stock. Two Sigma Investments LP purchased a new position in AquaBounty Technologies, Inc. (NASDAQ:AQB) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 37,565 shares of the company’s stock, valued at approximately $84,000. Two Sigma Investments LP owned 0.97% of AquaBounty Technologies as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 8.92% of the company’s stock.

About AquaBounty Technologies

AquaBounty Technologies, Inc is a biotechnology company focused on aquaculture innovation through the development and commercialization of genetically engineered fish. Its flagship product, AquAdvantage Salmon, is an Atlantic salmon strain enhanced with a growth hormone gene that enables faster growth and more efficient feed conversion compared with conventional farmed salmon. By integrating biotechnology into seafood production, AquaBounty aims to address global protein demand while reducing the environmental footprint associated with marine aquaculture.

Founded in 1991, AquaBounty is headquartered in Maynard, Massachusetts, and operates a state-of-the-art, land-based incubation and grow-out facility in Panama.